) with biopsy or removal of polyps performed at the time. The finding of any adenomatous polyp or other suspicious lesion prompts further evaluation with colonoscopy. Fifteen percent of such screenings result in referral for colonoscopy. 5 However, some have suggested that diminutive adenomas may not require follow-up -a policy that might reduce colonoscopy referrals to 5% of screenings. 6 FS is a safe procedure, with a reported colonic perforation rate of about 1 in 50 000. 7 Outpatient colonoscopy, which includes therapeutic procedures, has a perforation rate of about 1 in 1000. 8 Concerns are commonly raised about the potential miss rate of FS for lesions in the proximal colon beyond the reach of the instrument and of small lesions that are overlooked in the areas examined. Many heterogeneous studies have addressed the issues of missed proximal colonic lesions and of what distal colonic findings should trigger colonoscopic follow-up. The likelihood of a proximal advanced polyp (ie, one with pathological features that increase malignant potential, such as size or villous architecture) increases with a more advanced distal finding. In the absence of any distal adenoma, 2%-5% of asymptomatic people screened will have isolated proximal advanced lesions. 9 Whether this is acceptable in the context of cancer screening may become clear from prospective studies. The fact that sigmoidoscopy may also miss lesions within the area of colon that is examined may have implications for the screening intervals used. It has been shown on repeat FS that polyps may be missed in up to 20% of cases, 10 while with colonoscopy a 6% miss rate for adenomas larger than 1 cm has been reported. 11 Schoen et al 12 recently reported a 0.8% advanced adenoma or cancer rate (there were 6 cancers in 9317 repeat examinations) in patients having a repeat examination 3 years after an apparently normal examination; 80% of advanced lesions were in regions thought to have been adequately examined previously, indicating missed or newly evolved lesions. However, other studies have shown that after 5 years the rate of new findings is low enough to consider lengthening the screening interval. 5 The technical aspects of FS are sufficiently clear to enable us to define what FS can and cannot do. From the point of view of screening, FS clearly cannot completely exclude the presence of colon cancer in all asymptomatic people. A distinction must be made between screening the general population and testing the individual seeking screening. For the former, obtaining the greatest mortality benefit safely and at an acceptable cost to the nation is the crux of the matter. Recently published data indicate that FS is a costeffective screening strategy, although colonoscopy and annual FOBT avert a greater number of cancer deaths. 13 The results of randomised controlled trials of screening FS and colonoscopy, currently being conducted, will allow us to make a more accurate comparison with the established data regarding FOBT.
Participation rates in sigmoidoscopy screening (23% in initial screening and 54% in follow-up screening at our institution) are encouraging given the invasive nature of FS screening. 4, 5 The ability of Australian gastroenterologists to accommodate increased demand for colonoscopy, whether as a follow-up to FOBT or FS, remains to be seen.
Pieces of the jigsaw continue to fall into place, although it is likely to be some years before a clearly superior screening modality is determined. The emergence of new technologies
